Eli Lilly Exec Says Seeing Out of Pocket Payments for Obesity Drug in US
Favicon 
www.newsmax.com

Eli Lilly Exec Says Seeing Out of Pocket Payments for Obesity Drug in US

A top Eli Lilly (LLY.N), opens new tab executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.Patrik Jonsson, President of Lilly Diabetes and Obesity, speaking at a Goldman...